Ipsen Biopharma

ONIVYDE

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Ipsen Biopharma

Onivyde HCPCS:

J9205

HCPCS Code Descriptor:

Injection, irinotecan liposome, 1 mg

Category:

J Code

Onivyde NDCs:

15054-0043-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Onivyde CPT Codes:

Potential CPT administration codes for Onivyde can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Onivyde:

ONIVYDE is an Oncology drug manufactured by Ipsen Biopharma and administered via the Intravenous route of administration. The J Code: J9205 is aligned to the drug ONIVYDE.

Onivyde is a medicine often prescribed to patients with metastatic pancreatic cancer. Onivyde is approved for adults whose cancer has spread who have already tried other forms of chemotherapy. It is typically given in combination with two other medications, fluorouracil and leucovorin. It is typically administered by IV infusion.

ACCESS PRICING AND MORE BY REGISTERING

J9205 Added Date:

January 1, 2017

J9205 Effective Date:

January 1, 2017

J9205 Termination Date:

HCPCS Active

Onivyde billing and coding information can be found through Ipsen Biopharma at the link below:
Onivyde patient assistance information can be found through Ipsen Cares at the URL: http://www.ipsencares.com/
ONIVYDE prescribing information can be found at the link below:
Information regarding ONIVYDE’s side effects can be found at MedlinePlus